Clinically Relevant Resistance in Cancer Chemotherapy

  • Borje Andersson
  • David Murray

Part of the Cancer Treatment and Research book series (CTAR, volume 112)

Table of contents

  1. Front Matter
    Pages I-XX
  2. Marilyn L. Clarke, John R. Mackey, Stephen A. Baldwin, James D. Young, Carol E. Cass
    Pages 27-47
  3. Lei Deng, Shigaru Tatebe, Yen-Chiu Lin-Lee, Toshihisa Ishikawa, M. Tien Kuo
    Pages 49-66
  4. David Hamilton, Nasser Fotouhi-Ardakani, Gerald Batist
    Pages 67-87
  5. Steven Grant, Paul B. Fisher, Paul Dent
    Pages 89-108
  6. Randy J. Legerski, Christopher Richie
    Pages 109-128
  7. Henry S. Friedman, Stewart P. Johnson, O. Michael Colvin
    Pages 199-209
  8. Borje S. Andersson, David Murray
    Pages 211-235
  9. Michael Andreeff, Marina Konopleva
    Pages 237-262
  10. Jeannine S. McCune, John T. Slattery
    Pages 323-345
  11. Sambasivarao Damaraju, Michael Sawyer, Brent Zanke
    Pages 347-372
  12. Back Matter
    Pages 373-380

About this book


Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.


DNA cancer cell chemotherapy leukemia pharmacology radiation stem cell tumor

Editors and affiliations

  • Borje Andersson
    • 1
  • David Murray
    • 2
  1. 1.MD Anderson Cancer CenterHoustonUSA
  2. 2.Cross Cancer InstituteEdmontonCanada

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 2002
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-5428-4
  • Online ISBN 978-1-4615-1173-1
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site